Digestion of Protein in Premature and Term Infants.

Premature birth rates and premature infant morbidity remain discouragingly high. Improving nourishment for these infants is the key for accelerating their development and decreasing disease risk. Dietary protein is essential for growth and development of infants. Studies on protein nourishment for premature infants have focused on protein requirements for catch-up growth, nitrogen balance, and digestive protease concentrations and activities. However, little is known about the processes and products of protein digestion in the premature infant. This review briefly summarizes the protein requirements of term and preterm infants, and the protein content of milk from women delivering preterm and at term. An in-depth review is presented of the current knowledge of term and preterm infant dietary protein digestion, including human milk protease and anti-protease concentrations; neonatal intestinal pH, and enzyme activities and concentrations; and protein fermentation by intestinal bacteria. The advantages and disadvantages of incomplete protein digestion as well as factors that increase resistance to proteolysis of particular proteins are discussed. In order to better understand protein digestion in preterm and term infants, future studies should examine protein and peptide fragment products of digestion in saliva, gastric, intestinal and fecal samples, as well as the effects of the gut micro biome on protein degradation. The confluence of new mass spectrometry technology and new bioinformatics programs will now allow thorough identification of the array of peptides produced in the infant as they are digested

Nutritional intervention and impact of polyphenol on glycohaemoglobin (HbA1c) in non-diabetic and type 2 diabetic subjects: systematic review and meta-analysis

Polyphenols have been extensively studied for their antioxidant and anti-inflammatory properties. Recently, their antiglycative actions by oxidative stress modulation have been linked to prevention of diabetes and associated complications. This paper assesses the evidence for polyphenol interventions on glycohaemoglobin (HbA1c) in non-diabetic, pre-diabetic and type 2 diabetes mellitus (T2DM) subjects. A systematic review of polyphenols clinical trials on HbA1c in humans was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis. Thirty-six controlled randomized trials with HbA1c values were included. Polyphenols (extracts, supplements, foods), were supplemented (28 mg to 1.5g) for 0.7 to 12 months. Combining all subjects (n=1954, mean baseline HbA1c=7.03%, 53 mmol/mol), polyphenol supplementation significantly (p<0.001) lowered HbA1c% by -0.53±0.12 units (-5.79±0.13 mmol/mol). This reduction was significant (p<0.001) in T2DM subjects, specifically (n=1426, mean baseline HbA1c=7.44%, 58 mmol/mol), with HbA1c% lowered by -0.21±0.04 units (-2.29±0.4 mmol/mol). Polyphenol supplementation had no significant effect (p>0.21) in the non-diabetic (n=258, mean baseline HbA1c=5.47%, 36 mmol/mol) and the pre-diabetic subjects (n=270, mean baseline HbA1c=6.06%, 43 mmol/mol) strata: -0.39±0.27 HbA1c% units (-4.3±0.3 mmol/mol), and -0.38±0.31 units (-4.2±0.31 mmol/mol), respectively. In conclusion, polyphenols can successfully reduce HbA1c in T2DM, without any intervention at glycaemia, and could contribute to the prevention of diabetes complications

Determination of reliability and validity of the two modes of the Nikon Retinomax autorefractor

This study was designed to determine the reliability and validity of the two modes of the Nikon Retinomax Autorefractor. Reliability was determined by comparing readings within the regular mode and the quick mode. Ten consecutive readings, in each mode, were taken on 14 subjects ranging in age from 22 to 50. Validity of the quick mode was determined by comparing the readings of the quick mode to readings taken with the regular mode, 119 subjects between the ages of 5 and 88 participated. Results indicated that the findings are quite variable. Twenty five percent of the readings in the regular mode and 34% of the quick mode readings differed from the mean reading to a clinically significant degree using ANSI standards. However, when the data was compared using a less restrictive increment of +/- .25D, the reliability was greatly improved. In the validity analysis, the only significant difference between the modes was in the axis findings (p=.0264)

Degradation of oligomeric procyanidins and anthocyanins in a Tinta Roriz red wine during maturation

A young red Tinta Roriz wine was stored for three months at different temperatures (12, 22, 32, 42 degrees C) under anaerobic conditions and after adjusting the SO2 to 0, 50, 100 mg/l. Changes in wine phenolic composition, especially the procyanidins and anthocyanins were measured using HPLC reverse phase. Dimeric (B1, B2, B3, B4), galloylated dimeric (B1-3-O-gallate, B2-3O-gallate, B2-3'-O-gallate) and trimeric procyanidins (C1, T2) were quantified during the maturation of the red wine, and their losses were found to be logarithmic with time. Temperature exerts a marked influence on the progressive degradation of procyanidins, while the presence of SO, slows down the degradation. Comparing their activation energies the dimer procyanidins B1, B2 and B3 appear to be more stable to degradation while trimer T2 and B2-3-O-gallate are most reactive. Concerning the anthocyanins, the acylated monoglucosides degrade faster than the other monoglucosides and the p-coumaric acid acylated pigments disappear faster than the acetic acid acylated pigments

Mobile Link - A Theory-Based Messaging Intervention for Improving Sexual and Reproductive Health of Female Entertainment Workers in Cambodia: Study Protocol of a Randomized Controlled Trial

BACKGROUND: In Cambodia, HIV prevalence is concentrated in key populations including among female entertainment workers (FEWs) who may engage in direct or indirect sex work. Reaching FEWs with sexual and reproductive health (SRH) services has been difficult because of their hidden and stigmatized nature. Mobile-phone-based interventions may be an effective way to reach this population and connect them with the existing services. This article describes study design and implementation of a randomized controlled trial (RCT) of a mobile health intervention (the Mobile Link) aiming to improve SRH and related outcomes among FEWs in Cambodia. METHODS: A two-arm RCT will be used to determine the effectiveness of a mobile-phone-based text/voice messaging intervention. The intervention will be developed through a participatory process. Focus group discussions and in-depth interviews have been conducted to inform and tailor behavior change theory-based text and voice messages. During the implementation phase, 600 FEWs will be recruited and randomly assigned into one of the two arms: (1) a control group and (2) a mobile phone message group (either text messages [SMS] or voice messages [VM], a delivery method chosen by participants). Participants in the control group will also receive a weekly monitoring survey, which will provide real-time information to implementing partners to streamline outreach efforts and be able to quickly identify geographic trends. The primary outcome measures will include self-reported HIV and sexually transmitted infections (STI) testing and treatment, condom use, contraceptive use, and gender-based violence (GBV). DISCUSSION: If the Mobile Link trial is successful, participants will report an increase in condom use, linkages to screening and treatment for HIV and STI, and contraception use as well as a reduction in GBV. This trial is unique in a number of ways. First, the option of participation mode (SMS or VM) allows participants to choose the message medium that best links them to services. Second, this is the first RCT of a mobile-phone-based behavior change intervention using SMS/VMs to support linkage to SRH services in Cambodia. Lastly, we are working with a hidden, hard-to-reach, and dynamic population with which existing methods of outreach have not been fully successful. TRIAL REGISTRATION: Clinical trials.gov, NCT03117842 . Registered on 31 March 2017